Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia
- 10 August 2010
- journal article
- review article
- Published by Elsevier BV in European Journal of Pharmacology
- Vol. 639 (1-3), 59-66
- https://doi.org/10.1016/j.ejphar.2009.12.041
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- Differential Expression of Metabotropic Glutamate Receptors 2 and 3 in Schizophrenia: A Mechanism for Antipsychotic Drug Action?American Journal of Psychiatry, 2009
- Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDARNeuropharmacology, 2009
- Endogenous serotonin and serotonin2C receptors are involved in the ability of M100907 to suppress cortical glutamate release induced by NMDA receptor blockadeJournal of Neurochemistry, 2008
- Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophreniaTrends in Pharmacological Sciences, 2008
- Identification of a serotonin/glutamate receptor complex implicated in psychosisNature, 2008
- Phencyclidine and Dizocilpine Induced Behaviors Reduced by N-acetylaspartylglutamate Peptidase Inhibition via Metabotropic Glutamate ReceptorsBiological Psychiatry, 2008
- Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trialNature Medicine, 2007
- A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shellNeuroscience Letters, 2006
- A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese populationSchizophrenia Research, 2005
- Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene ( GRM3 ) with schizophreniaPsychiatric Genetics, 2003